National Institute of Allergy and Infectious Diseases (NIAID) http://www.niaid.nih.gov
FOR IMMEDIATE RELEASE Wednesday, June 6, 2007

WHAT:	The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), today released its NIAID Research Agenda for Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Tuberculosis (TB). While focusing on MDR/XDR TB, many of the research priorities identified in this document also relate to drug-sensitive tuberculosis. The research priorities identified in the agenda build on a foundation of ongoing NIAID-supported TB research, which currently comprises more than 300 research projects worldwide Diagnosing, treating and controlling the spread of TB has become increasingly complicated because of the HIV/AIDS co-epidemic and the emergence of MDR and XDR TB, which threatens to set TB control efforts back to the pre-antibiotic era. According to NIAID Director Anthony S. Fauci, M.D., NIAID developed this TB research agenda to address MDR/XDR TB with appropriate urgency, while reaffirming the Institute’s commitment to a robust program of research focused on all aspects of TB. NIAID is well prepared to foster the development of new TB diagnostics, drugs and vaccines, but given the realities of MDR/XDR TB, the research agenda outlines those areas that need additional attention to enable public health officials to more effectively combat all forms of tuberculosis, he says. He notes that the agenda is a Web-based “living document” that can be updated as scientific and public health needs and opportunities evolve. NIAID collaborated with other government and non-government experts to prepare the MDR/XDR TB research agenda. In addition to its review by TB specialists in academia, advocacy groups, international organizations and other government agencies, the draft agenda was presented to the National Advisory Allergy and Infectious Diseases Council, NIAID’s main scientific advisory body. The research agenda specifically describes six critical areas where additional investigation is needed to close gaps in our understanding of MDR/XDR TB and to improve the clinical management of people with TB: Finding new TB diagnostic tools  Improving therapy for all forms of TB, including MDR/XDR TB  Understanding basic biology and immunology of TB Studying MDR/XDR TB epidemiology   Enhancing the clinical management of MDR/XDR TB in people with or without HIV/AIDS Improving TB prevention strategies, including vaccines
REPORT:	The NIAID Research Agenda for Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Tuberculosis (TB) is available online. More information about NIAID research on TB, including funding opportunities is available at the NIAID Tuberculosis Topic.
CONTACT:	To schedule interviews, contact Jason Bardi in the NIAID News and Public Information Branch at (301) 402-1663, or niaidnews@niaid.nih.gov.

NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.

The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov

###

back to top